The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of more than 20 children’s hospitals that conduct clinical trials of new therapies for children with brain tumors with the mission to identify personalized treatment challenges.
PNOC was formed to provide children with brain tumors access to individual and personalized treatment based on the molecular biology and genetics of each tumor.
Participating hospitals include:
- Children’s Hospital Los Angeles (CHLA)
- The Children’s Hospital of Philadelphia (CHOP)
- Children’s National Medical Center (CNMC)
- Johns Hopkins Hospital
- Children’s Hospital & Research Center Oakland (CHRCO)
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center (DFCI)
- Nationwide Children’s Hospital (Nationwide)
- Doernbecher Children’s Hospital Oregon Health & Science University (OHSU)
- Jude Children’s Research Hospital (St Jude)
- University of California, Los Angeles (UCLA)
- University of California, San Diego Rady Children’s Hospital(UCSD/Rady)
- University of California, San Francisco (UCSF)
- University of Utah(UTAH)
- Seattle Children’s Hospital (Seattle)
- Louis Children’s Hospital
- Texas Children’s Hospital
- University of Minnesota/Masonic Cancer Center
- UF Health Neuromedicine Hospital
- Ann & Robert H. Lurie Children’s Hospital of Chicago
- The Children’s Hospital of Philadelphia
- SickKids Hospital
PNOC is running clinical trials like nanoliposomal irinotecan and immunotherapy vaccine (H3.3K27M) for Diffuse Intrinsic Pontine Glioma, modified measles virus for recurrent medulloblastoma, Everolimus for recurrent or progressive low-grade gliomas, Vemurafenib for children with recurrent/ refractory BRAFV600E-mutant gliomas.
To find out if your child is eligible to enroll in a PNOC clinical trial you have to contact the closest participating site.